MedTrace Logo

Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury

NCT04379011 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-10-14

Study results available
· View outcomes & findings →

Summary

Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to all pharmacological intervention. Preliminary data suggest brivarecetum is a mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized, placebo-controlled pilot clinical trial will assess feasibility of a 3-month treatment course with brivarecetum.

Conditions

  • Spinal Cord Injuries

Interventions

DRUG

Brivaracetam

Escalating brivaracetam dose to 150 mg twice daily for 3 months

OTHER

Placebo

Placebo twice daily for 3 months

Sponsors & Collaborators

Principal Investigators

  • Leslie Morse, DO · University of Minnesota

  • Scott Falci, MD · Swedish Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2024-03-31
Completion
2024-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04379011 on ClinicalTrials.gov